Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:tipranavir
|
| gptkbp:approvalYear |
2005
|
| gptkbp:ATCCode |
J05AE09
|
| gptkbp:CASNumber |
212141-51-0
|
| gptkbp:chemicalFormula |
C31H33F3N2O5S
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:drugClass |
protease inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aptivus
|
| gptkbp:indication |
treatment-experienced HIV patients
|
| gptkbp:isCombinationDrug |
no
|
| gptkbp:KEGGID |
gptkb:D06013
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Boehringer_Ingelheim
|
| gptkbp:mechanismOfAction |
inhibits HIV-1 protease
|
| gptkbp:oftenCoAdministeredWith |
gptkb:ritonavir
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
148192
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
rash hepatotoxicity |
| gptkbp:UNII |
JX5OHT5B5K
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Tipranavir
|
| gptkbp:bfsLayer |
7
|